Work Here?
Cullinan Oncology
Work Here?
Develops diversified oncology assets via portfolio
Cullinan Oncology
Work Here?
Develops diversified oncology assets via portfolio
Overview
Cullinan Oncology develops cancer treatments by managing a diverse set of oncology assets using a portfolio approach. The company advances therapies from preclinical stages to Phase 2 clinical trials, either on its own or through partnerships, and generates revenue from development and eventual commercialization. Its product(s) work by progressing promising compounds through clinical trials to show safety and efficacy across different cancer types, with a focus on mechanisms of action that broaden potential benefits. Cullinan differentiates itself with a modern portfolio theory-inspired asset mix, aiming to balance risk and return across many indications while maintaining a lean structure with almost no fixed costs for capital efficiency. The goal is to bring transformative cancer therapies to patients and improve the standard of care, pursuing both internal development and strategic partnerships to maximize value.
About Cullinan Oncology
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2017
Simplify's Take
What believers are saying
- EGFR-NSCLC market grows 9.6% CAGR to $6B by 2034 led by zipalertinib.
- $280M oversubscribed placement funds development through 2026.
- Taiho partnership yields $275M upfront plus $130M milestones.
What critics are saying
- ArriVent's adagrasib beats zipalertinib PFS eroding U.S. share in 6-12 months.
- BMS bispecifics capture frontline NSCLC blocking zipalertinib in 12-18 months.
- AbbVie ADCs with 80% ORR displace zipalertinib revenue in 12-24 months.
What makes Cullinan Oncology unique
- Cullinan uses portfolio model diversifying oncology assets across indications.
- Lean infrastructure ensures nearly zero fixed costs for capital efficiency.
- Zipalertinib selectively targets EGFR exon 20 insertions sparing wild-type EGFR.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$947.1M
Above
Industry Average
Funded Over
5 Rounds
Benefits
Remote Work Options
Stock Price
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 3%2 year growth
↑ 4%DelveInsight forecasts the EGFR-NSCLC market will grow at a 9.6% CAGR from 2025 to 2034, reaching $6 billion across seven major markets in 2024. The United States accounts for the largest market share. Growth drivers include approval of new therapies such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), and Sacituzumab Tirumotecan (Merck/Kelun-Biotech) in frontline and combination settings, rising therapy costs, and increasing testing rates enabling identification of more EGFR-positive patients. The emerging pipeline includes TKIs, antibody-drug conjugates, bispecifics, and gene therapies from companies including ArriVent BioPharma, Bristol-Myers Squibb, and AbbVie. Adenocarcinoma represents the highest number of histology-specific cases. Recent clinical trials show promising results, with some candidates demonstrating over 80% objective response rates in treatment-naïve patients.
Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to...
Federated Hermes Inc. acquires new Holdings in Cullinan Oncology, Inc. (NASDAQ:CGEM).
Algert Global LLC invests $150,000 in Cullinan Oncology, Inc. (NASDAQ:CGEM).
Under Mr. Hughes's leadership, Cullinan raised over $400 million in capital through its initial public offering and advanced several assets into the clinic.
Cullinan Oncology is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Cullinan Oncology
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Cambridge, Massachusetts
Founded
2017
Cullinan Oncology is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today